The severe forms of asthma represent a major burden, because of severity of symptoms, costs and impact on everyday life. Recently, Mepolizumab (MEP) was approved and marketed for the treatment of hypereosinoph… Lesen Sie weiter auf: The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials Quelle: World Allergy Organization Journal Titelbild/Grafik […]